Find Clinical Trials

181 Results

Protocol Code	Study Title	Active Substance	Study Phase	Therapeutic Area
CL1-65487-002	Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non…	S65487 /	Phase 1	Oncology
CL1-64315-002	An International Phase Ib Multicentre Study to Characterize the Safety and Tolerability of Intravenously Administered…	S064315 /	Phase 1	Oncology
CL3-95008-002	Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less…	BUMETANIDE / S095008 /	Phase 3	Neurosciences
CL3-95008-001	Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7…	BUMETANIDE / S095008 /	Phase 3	Neurosciences
CL2-201086-002	Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with…	S201086 /	Phase 2	Rhumatology
Control-2	Efficacy of ivabradine in combination with beta-blockers vs up-titration of beta-blockers in daily practice	IVABRADINE - S016257 /	Phase 4	Cardiovascular
CL3-05153-008	A clinical study to test the safety and the efficacy of a single-pill combination of…	AMLODIPINE / ATORVASTATIN / ATORVASTATIN - AMLODIPINE - PERINDOPRIL ARGININE - S005153 / PERINDOPRIL / S005153 /	Phase 3	Cardiovascular
CL3-05682-109	Clinical non-inferiority study between Micronized purified flavonoid fraction 1000 mg, one chewable tablet per day…	MICRONISED PURIFIED FLAVONOID FRACTION / S005682 /	Phase 3	Cardiovascular
CL1-95010-001	Safety, Tolerability and Pharmacokinetics of S 95010 After Single Escalating Intravenous Doses in Young Healthy…	S095010 /	Phase 1	Cardiovascular
CL3-95005-006	An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to…	TIPIRACIL / TRIFLURIDINE / TRIFLURIDINE - TIPIRACIL /	Phase 3	Oncology
CL1-81694-003	Phase I/II trial of S 81694 administered intravenously in combination with paclitaxel to evaluate the…	S081694 /	Phase 1-2	Oncology
CL1-49076-002	Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with…	S049076 /	Phase 1-2	Oncology
CL1-80881-002	INES - Phase Ib dose allocation study of oral administration of lucitanib given in combination…	LUCITANIB /	Phase 1	Oncology
CL1-68587-001	A phase 1, open label, non-comparative, monocenter study to evaluate the safety and the ability…	S068587 / S068587 - UCART19 / UCART19 /	Phase 1	Oncology
IC4-95005-183-DEU	Prospective, Multicenter, Open-label Phase IV trial of Trifluridine/Tipiracil to Evaluate the Health-related Quality of Life…	TIPIRACIL / TRIFLURIDINE / TRIFLURIDINE - TIPIRACIL /	Phase 4	Oncology
SC3-90049-001	Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg…	PIRIBEDIL /	Phase 3	Neurosciences
SC2-90049-003	Effect of 3 doses (20, 40 and 60 mg) of a sublingual formulation of piribedil…	PIRIBEDIL /	Phase 2	Neurosciences
PKH-05720-001	A study to assess the release profiles from fixed combination tablets (gliclazide MR/metformin)	GLICLAZIDE / GLICLAZIDE - METFORMINE - S005720 / METFORMINE / S005720 /	Phase 1	Metabolism
MC3-06790-001	Study of the effect of trimetazidine MR 35 mg (2 tabs/day) on the emergence of…	TRIMETAZIDINE /	Phase 3	Cardiovascular
IC4-5702-205-CHN	Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat…		Phase 4	Metabolism
IC4-20098-542	Efficacy and safety of Valdoxan® given orally once a day for 24 weeks in patients…	AGOMELATINE / AGOMELATINE - S020098 / S020098 /	Phase 4	Neurosciences
IC4-12911-098	PRotelos 2g in the OSteoporosis treatment, the Tolerability and Efficacy Profile - PROSTEP	STRONTIUM / STRONTIUM RANELATE /	Phase 4	Rhumatology
IC4-05682-099	Efficacy of Detralex® in Edema Treatment. An open, 6-month, multicentre study. EDET Study	MICRONISED PURIFIED FLAVONOID FRACTION /	Phase 4	Cardiovascular
IC4-05682-031	Detralex* versus placebo in the treatment of acute hemorrhoids in patients with acute hemorrhoidal attack.…	MICRONISED PURIFIED FLAVONOID FRACTION /	Phase 4	Cardiovascular
DM4-90652-001	Patient pREference and satisFaction for pErindopril oRodispersible vs convENtional tablets in daily Clinical practicE. PREFERENCE	PERINDOPRIL / PERINDOPRIL ARGININE /	Phase 4	Cardiovascular